It relates to a therapeutic agent containing nucleic acid and TCR modified immune cells and its application. The therapeutic agent includes a first composition containing a first active ingredient and a second composition containing a second active ingredient； the first active ingredient includes or contains a labeled polypeptide for introduction into tumor cells and/or cancer cells A nucleic acid encoding a sequence； the labeled polypeptide has one or more amino acid sequences of an epitope polypeptide, and the epitope polypeptide can be presented on the surface of the tumor cell and/or cancer cell by MHC class I molecules； the second combination The substance contains a second active ingredient in a second pharmaceutically acceptable carrier, and the second active ingredient contains immune cells modified by T cell receptors； the immune cells modified by T cell receptors can specifically recognize and bind to The epitope polypeptide presented by MHC class I molecules. The invention realizes the synergistic treatment effect and provides a new way for tumor treatment.涉及包含核酸及TCR修飾的免疫細胞的治療劑及其應用。該治療劑包含含有第一活性成分的第一組合物和含有第二活性成分的第二組合物；該第一活性成分包括或含有用於導入腫瘤細胞及/或癌細胞的、具有標記性多肽編碼序列的核酸；該標記性多肽具有一個或多個抗原表位多肽的氨基酸序列，該抗原表位多肽能夠被MHC I類分子提呈在該腫瘤細胞及/或癌細胞表面；該第二組合物包含位於第二可藥用載體中的第二活性成分，該第二活性成分包含T細胞受體修飾的免疫細胞；所述的T細胞受體修飾的免疫細胞能夠特異性識別並結合被該MHC I類分子提呈的該抗原表位多肽。本發明實現了協同治療效果，為腫瘤治療提供了一個新的途徑。
